Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 43INDUSTRY 17NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Mucinous Adenocarcinoma 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Endometrioid 1Carcinoma in Situ 1Carcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Doxorubicin 9Specimen Handling 7Sorafenib 7Erlotinib Hydrochloride 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Fluorouracil 5Thalidomide 4Radiofrequency Ablation 4Bevacizumab 4tremelimumab 3cediranib 3cabozantinib 3Trastuzumab 3Pharmacogenomic Testing 3Nivolumab 3Neoadjuvant Therapy 3Melphalan 3MK 2206 3Irinotecan 3Fluorodeoxyglucose F18 3Dasatinib 3Cisplatin 3Chemotherapy, Adjuvant 3Bortezomib 3Biopsy 3AZD 6244 3trametinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma, Hepatocellular × durvalumab × Clear all
NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡